ARS Pharma develops and sells neffy, a nasal spray form of epinephrine for emergency treatment of severe allergic reactions. It last closed at $2.96 on Nov 20, down 11.90% on the day. The next earnings report for SPRY is expected around Mon, Mar 8, 2027. For the quarter ended Sep 2026, SPRY reported EPS of -$0.36 on revenue of $37.7M, with revenue up 16.0% from a year ago. Over its last 8 reports the stock moved an average of 7.1% the session after earnings. Over the last 12 months SPRY insiders bought $0 of stock on the open market and sold $284K, according to SEC Form 4 filings.
AI Auto Pilots
Is SPRY in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold SPRY.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on SPRYStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
SPRY · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 16% below its 20 day and 32% below its 50 day average. It is 132% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 37), near oversold. The nearest support is the Pivot S1 at $2.72, and the nearest resistance the Pivot at $3.09.
Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 13.2%/day
Key levels
$13.1552 week high+344.3%
$6.87200 day average+132.1%
$5.06100 day average+70.9%
$4.13Swing high (Nov 11)+39.5%
$3.9050 day average+31.8%
$3.4320 day average+15.9%
$3.33Pivot R1+12.5%
$3.09Pivot+4.4%
$2.96Last close
$2.72Pivot S1−8.1%
$2.4452 week low−17.6%
$2.44Swing low (Nov 6)−17.6%
Indicators
RSI (14)
36.99
Weak, oversold below 30
Neutral
MACD
-0.17
Above its signal line
Bullish
Stochastic
53.1
Middle of its range
Neutral
ADX (14)
21.7
Weak trend
Williams %R
-69.2
Oversold below −80, overbought above −20
Neutral
CCI (20)
-70.0
Oversold below −100, overbought above 100
Neutral
Rate of change
+6.1%
Change over 10 sessions
Bullish
ATR (14)
$0.39
Typical daily range, 13.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 33.4%/day
Key levels
$13.1552 week high+344.3%
$6.87200 day average+132.1%
$5.06100 day average+70.9%
$4.13Swing high (Nov 11)+39.5%
$3.9050 day average+31.8%
$3.4320 day average+15.9%
$3.33Pivot R1+12.5%
$3.09Pivot+4.4%
$2.96Last close
$2.72Pivot S1−8.1%
$2.4452 week low−17.6%
$2.44Swing low (Nov 6)−17.6%
Indicators
RSI (14)
32.30
Weak, oversold below 30
Neutral
MACD
-1.29
Below its signal line
Bearish
Stochastic
18.7
Near the bottom of its range
Oversold
ADX (14)
36.2
Trending down
Williams %R
-87.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-102.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−37.8%
Change over 10 sessions
Bearish
ATR (14)
$0.99
Typical daily range, 33.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SPRY
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how SPRY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow SPRY usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for SPRYHow many large options trades hit SPRY, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in SPRY in the last 90 days.
From SEC Form 4 filings by SPRY's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SPRY is in one of them and how their past SPRY trades turned out.
ARS Pharma is a biopharmaceutical company that develops and sells neffy, an epinephrine nasal spray for emergency treatment of allergic reactions, including anaphylaxis. The product is given through the nose without a needle, and it is sold under other trade names in Europe, the U.K. and China. Its customers include patients, caregivers, and the doctors who prescribe it, and partners help commercialize the product in several countries. The company is headquartered in San Diego, California.